Recipharm increases blow fill seal capacity in Kaysersberg, France
![](/46/pdcnewsitem/04/15/68/recpharm.jpg)
Yves Buelens, General Manager at Recipharm’s Kaysersberg site
The investment will bring the total number of lines to eight, to meet the growing demand of the service.
Recipharm has invested €18 million to expand its blow fill seal capacity at its site in Kaysersberg, France.
The investment will see the introduction of a new blow fill seal high speed filling and packaging line, bringing the total number of lines from seven to eight to meet growing demand for the service.
Preparations will also be made to add a further three filling lines over the coming years, more than doubling the size of the CDMO’s operations from 2,000 square metres to 4,150 square metres and increasing its blow fill seal capacity by 50%. The first of the four planned filling lines will allow Recipharm to support more drug developers with the aseptic processing of sterile liquids such as eye care and ear drops into plastic containers.
Yves Buelens, General Manager at Recipharm’s Kaysersberg site, said: “We are experiencing increased demand for our blow fill seal services from markets including the US, Turkey, Australia and Canada and the new filling line will help us to meet this growing need.”
“The increased capacity will position us well for future growth and allow us to take on new projects from new customers more swiftly. With the site’s big pharma heritage, we are ideally placed to meet the highest quality and regulatory requirements and are committed to investing in the facility to ensure we can continue to deliver the best possible service.”
Recipharm serves 250+ customers globally, offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs and pharmaceutical product development. The Kaysersberg site, located in Alsace, France, is a sterile facility specialising in blow fill seal technology for sterile liquids. The site manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications in plastic containers.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance